As GSK is forced to slam the brakes, Pfizer cruises ahead with a ‘breakthrough’ on RSV
Pfizer was a late arrival to the heavyweight Phase III fight to gain a first approval for an RSV vaccine, but the pharma giant has shown plenty of promise in making up lost time. And they’re kicking up their heels as rival GlaxoSmithKline has to suffer through a clinical hold that presents a serious setback for their own efforts.
The multinational player, which has enjoyed a mother lode of rewards from its Covid-19 franchise, just picked up breakthrough therapy designation status for its late-stage play here. A BTD is certainly no guarantee of success, but the chance to keep all doors at the FDA wide open as it makes its way through their pivotal trial offers the possibility of a faster approval — and that carries some big rewards when you’re up against a GSK or J&J, which also has its own contender in the fight.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.